CN109476627B - 用于治疗中枢神经系统和血管系统的病变的酚类化合物及其与稠合于1,4-二氢吡啶的苯并二氮杂卓的组合 - Google Patents

用于治疗中枢神经系统和血管系统的病变的酚类化合物及其与稠合于1,4-二氢吡啶的苯并二氮杂卓的组合 Download PDF

Info

Publication number
CN109476627B
CN109476627B CN201780040492.9A CN201780040492A CN109476627B CN 109476627 B CN109476627 B CN 109476627B CN 201780040492 A CN201780040492 A CN 201780040492A CN 109476627 B CN109476627 B CN 109476627B
Authority
CN
China
Prior art keywords
disease
dihydropyridine
central nervous
treatment
fused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780040492.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN109476627A (zh
Inventor
E·奥乔亚罗德里格斯
Y·贝尔德西亚雷耶斯
Y·努涅斯菲格雷多
J·拉米雷斯桑切斯
M·王格拉
L·A·丰塞卡丰塞卡
G·L·帕尔多安德鲁
C·A·卡南-哈登纳瓦罗
A·蒙德洛罗德里格斯
P·G·巴尔扎加费尔南德斯
N·冈萨雷斯阿方索
R·德尔加多埃尔南德斯
A·S·帕德龙雅奎斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de la Habana
Centro de Investigacion y Desarrollo de Medicamentos CIDEM
Original Assignee
Universidad de la Habana
Centro de Investigacion y Desarrollo de Medicamentos CIDEM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de la Habana, Centro de Investigacion y Desarrollo de Medicamentos CIDEM filed Critical Universidad de la Habana
Publication of CN109476627A publication Critical patent/CN109476627A/zh
Application granted granted Critical
Publication of CN109476627B publication Critical patent/CN109476627B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
CN201780040492.9A 2016-05-04 2017-05-03 用于治疗中枢神经系统和血管系统的病变的酚类化合物及其与稠合于1,4-二氢吡啶的苯并二氮杂卓的组合 Expired - Fee Related CN109476627B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2016000059A CU24576B1 (es) 2016-05-04 2016-05-04 Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular
CU2016-0059 2016-05-04
PCT/CU2017/050003 WO2017190714A1 (es) 2016-05-04 2017-05-03 Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular

Publications (2)

Publication Number Publication Date
CN109476627A CN109476627A (zh) 2019-03-15
CN109476627B true CN109476627B (zh) 2021-06-15

Family

ID=60202803

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780040492.9A Expired - Fee Related CN109476627B (zh) 2016-05-04 2017-05-03 用于治疗中枢神经系统和血管系统的病变的酚类化合物及其与稠合于1,4-二氢吡啶的苯并二氮杂卓的组合

Country Status (19)

Country Link
US (1) US10722491B2 (https=)
EP (1) EP3453704B1 (https=)
JP (1) JP6997995B2 (https=)
KR (1) KR102416478B1 (https=)
CN (1) CN109476627B (https=)
AR (1) AR108370A1 (https=)
AU (1) AU2017259749C1 (https=)
BR (1) BR112018072579B1 (https=)
CA (1) CA3023073C (https=)
CL (1) CL2018003114A1 (https=)
CO (1) CO2018011927A2 (https=)
CU (1) CU24576B1 (https=)
EA (1) EA037951B1 (https=)
ES (1) ES2878579T3 (https=)
MX (1) MX384967B (https=)
PH (1) PH12018502327A1 (https=)
SG (1) SG11201809843SA (https=)
WO (1) WO2017190714A1 (https=)
ZA (1) ZA201808161B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20160058A7 (es) 2016-05-04 2017-12-08 Centro De Investigación Y Desarrollo De Medicamentos (Cidem) Organizacion Superior De Desarrollo Emp Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular
AU2019361735A1 (en) * 2018-10-16 2021-05-27 Saban Ventures Pty Limited Apparatus and method for cleaning a medical device
CU20190114A7 (es) 2019-12-26 2021-08-06 Centro De Investig Y Desarrollo De Medicamentos Cidem Combinación para simultáneamente incrementar la eficacia analgésica de la morfina y reducir su dependencia física
BR112022012699A2 (pt) * 2019-12-26 2022-09-06 Centro De Investig Y Desarrollo De Medicamentos Cidem Uso de um derivado de benzodiazepina e método de tratamento de lesão cerebral traumática

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007063444A (ja) * 2005-08-31 2007-03-15 Tdk Corp 錯化合物及びこれを用いた光記録媒体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281714A (en) 1990-08-16 1994-01-25 American Home Products Corporation N,N',N'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA: cholesterol-acyl transferase
MX9204939A (es) 1991-09-06 1993-03-01 American Home Prod Inhibidores 5-bis-aminometilen-1,3-dioxan-4,6-diona n,n',n'-trisubstituidas, de la acil coenzima a: colesterol-aciltransferasa.
DE69202564T2 (de) 1992-07-17 1995-09-28 Biogal Gyogyszergyar Verfahren zur Herstellung von 1,3-Dioxan-4,6-Dionderivaten.
JPH11180975A (ja) 1997-10-13 1999-07-06 Chemiprokasei Kaisha Ltd アミノメチレンジオキサン誘導体、その製造方法および用途
JP5299810B2 (ja) 2004-02-27 2013-09-25 アムジエン・インコーポレーテツド 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007063444A (ja) * 2005-08-31 2007-03-15 Tdk Corp 錯化合物及びこれを用いた光記録媒体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Nrf2–ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases;Izaskun Buendia等;《Pharmacology & Therapeutics》;20151123;第157卷;第84-104页 *
Synthesis and biological evaluation of arylidene analogues of Meldrum’s acid as a new class of antimalarial and antioxidant agents;Harmeet S. Sandhu等;《Bioorganic & Medicinal Chemistry》;20100617;第18卷;第5626-5633页 *

Also Published As

Publication number Publication date
BR112018072579A2 (pt) 2019-02-19
EP3453704B1 (en) 2021-06-16
JP2019516791A (ja) 2019-06-20
US20190133996A1 (en) 2019-05-09
AR108370A1 (es) 2018-08-15
AU2017259749A1 (en) 2018-12-20
CA3023073A1 (en) 2017-11-09
CA3023073C (en) 2022-08-30
AU2017259749B2 (en) 2021-08-19
EA037951B1 (ru) 2021-06-11
CU20160059A7 (es) 2017-12-08
KR20210025138A (ko) 2021-03-09
AU2017259749C1 (en) 2021-12-02
JP6997995B2 (ja) 2022-02-04
SG11201809843SA (en) 2018-12-28
EP3453704A1 (en) 2019-03-13
ZA201808161B (en) 2021-10-27
MX384967B (es) 2025-03-14
CN109476627A (zh) 2019-03-15
BR112018072579B1 (pt) 2024-02-20
CO2018011927A2 (es) 2019-02-08
EA201892462A1 (ru) 2019-07-31
KR102416478B1 (ko) 2022-07-04
CL2018003114A1 (es) 2019-06-14
US10722491B2 (en) 2020-07-28
ES2878579T3 (es) 2021-11-19
PH12018502327A1 (en) 2019-09-02
WO2017190714A1 (es) 2017-11-09
MX2018013422A (es) 2019-08-16
CU24576B1 (es) 2022-02-04

Similar Documents

Publication Publication Date Title
US20200347153A1 (en) Methods for forming inclusion complexes with hydrophilic beta-cyclodextrin derivatives and compositions thereof
CN109476627B (zh) 用于治疗中枢神经系统和血管系统的病变的酚类化合物及其与稠合于1,4-二氢吡啶的苯并二氮杂卓的组合
WO2013120040A1 (en) Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy
RU2591210C2 (ru) Соединения и способы лечения боли и других расстройств
CA2432543A1 (en) Combination drugs
HK1261881A1 (en) Phenol compound and combination of same with a benzodiazepine fused to 1,4-dihydropyridine for treating diseases of the central nervous and vascular systems
KR102428383B1 (ko) 중추신경계 및 혈관계에 대한 활성을 가진 벤조디아제핀 생성물
TWI870751B (zh) 心腦血管藥物及其應用
CN117843573A (zh) 一种基于依达拉奉结构的前体化合物及其制备方法和应用
CN113185447B (zh) 邻苯二甲酰半胱酰胺类化合物、其制备方法和用途
HK1261881B (zh) 用於治疗中枢神经系统和血管系统的病变的酚类化合物及其与稠合於1，4-二氢吡啶的苯并二氮杂卓的组合
US12128019B1 (en) Nanocomposite including abscisic acid-loaded collagen nanoparticles
CN114853715B (zh) 一种有机亚硝酸根供体缩酮型前药及其制备方法与医药用途
RU2506950C2 (ru) Комбинация карбостирила и карнитина
TWI354672B (en) Antioxidants
EA046099B1 (ru) Применение продукта на основе бензодиазепина с активностью для профилактики и лечения деменции
CN116410160A (zh) 一种牛蒡子苷元衍生物及其制备方法与应用
HK40005140A (en) Benzodiazepine derivative with activity on the central nervous and vascular systems
EA041342B1 (ru) Применение продукта на основе бензодиазепина с активностью для профилактики и лечения болезни паркинсона
EA044367B1 (ru) Продукт на основе бензодиазепина с активностью на невропатическую боль
CN106588775A (zh) 一种吲唑衍生物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261881

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210615